241 related articles for article (PubMed ID: 35788562)
1. Critically ill COVID-19 patients with neutralizing autoantibodies against type I interferons have increased risk of herpesvirus disease.
Busnadiego I; Abela IA; Frey PM; Hofmaenner DA; Scheier TC; Schuepbach RA; Buehler PK; Brugger SD; Hale BG
PLoS Biol; 2022 Jul; 20(7):e3001709. PubMed ID: 35788562
[TBL] [Abstract][Full Text] [Related]
2. Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia.
de Prost N; Bastard P; Arrestier R; Fourati S; Mahévas M; Burrel S; Dorgham K; Gorochov G; Tandjaoui-Lambiotte Y; Azzaoui I; Fernandes I; Combes A; Casanova JL; Mekontso-Dessap A; Luyt CE
J Clin Immunol; 2021 Apr; 41(3):536-544. PubMed ID: 33616813
[TBL] [Abstract][Full Text] [Related]
3. Autoantibodies Neutralizing Type III Interferons Are Uncommon in Patients with Severe Coronavirus Disease 2019 Pneumonia.
Vanker M; Särekannu K; Fekkar A; Jørgensen SE; Haljasmägi L; Kallaste A; Kisand K; Lember M; Peterson P; Menon M; Hussell T; Knight S; Moore-Stanley J; Bastard P; Zhang SY; Mogensen TH; Philippot Q; Zhang Q; Puel A; Casanova JL; Kisand K
J Interferon Cytokine Res; 2023 Sep; 43(9):379-393. PubMed ID: 37253131
[TBL] [Abstract][Full Text] [Related]
4. Microarray-Based Detection of Antibodies against SARS-CoV-2 Proteins, Common Respiratory Viruses and Type I Interferons.
Savvateeva E; Filippova M; Valuev-Elliston V; Nuralieva N; Yukina M; Troshina E; Baklaushev V; Ivanov A; Gryadunov D
Viruses; 2021 Dec; 13(12):. PubMed ID: 34960822
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 mRNA vaccine, but not a viral vector-based vaccine, promotes neutralizing anti-type I interferon autoantibody production in a small group of healthy individuals.
Xu W; Wen X; Cong X; Jiang W
J Med Virol; 2023 Oct; 95(10):e29137. PubMed ID: 37792386
[TBL] [Abstract][Full Text] [Related]
6. Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain.
Troya J; Bastard P; Planas-Serra L; Ryan P; Ruiz M; de Carranza M; Torres J; Martínez A; Abel L; Casanova JL; Pujol A
J Clin Immunol; 2021 Jul; 41(5):914-922. PubMed ID: 33851338
[TBL] [Abstract][Full Text] [Related]
7. Early and Rapid Identification of COVID-19 Patients with Neutralizing Type I Interferon Auto-antibodies.
Akbil B; Meyer T; Stubbemann P; Thibeault C; Staudacher O; Niemeyer D; Jansen J; Mühlemann B; Doehn J; Tabeling C; Nusshag C; Hirzel C; Sanchez DS; Nieters A; Lother A; Duerschmied D; Schallner N; Lieberum JN; August D; Rieg S; Falcone V; Hengel H; Kölsch U; Unterwalder N; Hübner RH; Jones TC; Suttorp N; Drosten C; Warnatz K; Spinetti T; Schefold JC; Dörner T; Sander LE; Corman VM; Merle U; ; Kurth F; von Bernuth H; Meisel C; Goffinet C
J Clin Immunol; 2022 Aug; 42(6):1111-1129. PubMed ID: 35511314
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 is associated with bystander polyclonal autoreactive B cell activation as reflected by a broad autoantibody production, but none is linked to disease severity.
Jiang W; Johnson D; Adekunle R; Heather H; Xu W; Cong X; Wu X; Fan H; Andersson LM; Robertson J; Gisslén M
J Med Virol; 2023 Jan; 95(1):e28134. PubMed ID: 36086941
[TBL] [Abstract][Full Text] [Related]
9. Pre-existing Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-19 Patients Admitted to Intensive Care in Barcelona.
Solanich X; Rigo-Bonnin R; Gumucio VD; Bastard P; Rosain J; Philippot Q; Perez-Fernandez XL; Fuset-Cabanes MP; Gordillo-Benitez MÁ; Suarez-Cuartin G; Boza-Hernandez E; Riera-Mestre A; Parra-Martínez A; Colobran R; Antolí A; Navarro S; Rocamora-Blanch G; Framil M; Calatayud L; Corbella X; Casanova JL; Morandeira F; Sabater-Riera J
J Clin Immunol; 2021 Nov; 41(8):1733-1744. PubMed ID: 34570326
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of Neutralizing Autoantibodies Against Type I Interferon in a Multicenter Cohort of Severe or Critical COVID-19 Cases in Shanghai.
Shi D; Chen J; Zhao M; Tang Y; Zhao C; Jin Y; Tian D; Liao Y; Wang X; Wang W; Fan X; Yi Z; Chen X; Ling Y
J Clin Immunol; 2024 Mar; 44(3):80. PubMed ID: 38462559
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies against type I interferons in COVID-19 infection: A systematic review and meta-analysis.
Wang X; Tang Q; Li H; Jiang H; Xu J; Bergquist R; Qin Z
Int J Infect Dis; 2023 May; 130():147-152. PubMed ID: 36907547
[TBL] [Abstract][Full Text] [Related]
12. Autoantibodies against type I IFNs in patients with life-threatening COVID-19.
Bastard P; Rosen LB; Zhang Q; Michailidis E; Hoffmann HH; Zhang Y; Dorgham K; Philippot Q; Rosain J; Béziat V; Manry J; Shaw E; Haljasmägi L; Peterson P; Lorenzo L; Bizien L; Trouillet-Assant S; Dobbs K; de Jesus AA; Belot A; Kallaste A; Catherinot E; Tandjaoui-Lambiotte Y; Le Pen J; Kerner G; Bigio B; Seeleuthner Y; Yang R; Bolze A; Spaan AN; Delmonte OM; Abers MS; Aiuti A; Casari G; Lampasona V; Piemonti L; Ciceri F; Bilguvar K; Lifton RP; Vasse M; Smadja DM; Migaud M; Hadjadj J; Terrier B; Duffy D; Quintana-Murci L; van de Beek D; Roussel L; Vinh DC; Tangye SG; Haerynck F; Dalmau D; Martinez-Picado J; Brodin P; Nussenzweig MC; Boisson-Dupuis S; Rodríguez-Gallego C; Vogt G; Mogensen TH; Oler AJ; Gu J; Burbelo PD; Cohen JI; Biondi A; Bettini LR; D'Angio M; Bonfanti P; Rossignol P; Mayaux J; Rieux-Laucat F; Husebye ES; Fusco F; Ursini MV; Imberti L; Sottini A; Paghera S; Quiros-Roldan E; Rossi C; Castagnoli R; Montagna D; Licari A; Marseglia GL; Duval X; Ghosn J; ; ; ; ; ; ; ; ; ; ; Tsang JS; Goldbach-Mansky R; Kisand K; Lionakis MS; Puel A; Zhang SY; Holland SM; Gorochov G; Jouanguy E; Rice CM; Cobat A; Notarangelo LD; Abel L; Su HC; Casanova JL
Science; 2020 Oct; 370(6515):. PubMed ID: 32972996
[TBL] [Abstract][Full Text] [Related]
13. Autoantibodies Neutralizing Type I Interferons in 20% of COVID-19 Deaths in a French Hospital.
Chauvineau-Grenier A; Bastard P; Servajean A; Gervais A; Rosain J; Jouanguy E; Cobat A; Casanova JL; Rossi B
J Clin Immunol; 2022 Apr; 42(3):459-470. PubMed ID: 35083626
[TBL] [Abstract][Full Text] [Related]
14. Increased Presence of Antibodies against Type I Interferons and Human Endogenous Retrovirus W in Intensive Care Unit COVID-19 Patients.
Simula ER; Manca MA; Noli M; Jasemi S; Ruberto S; Uzzau S; Rubino S; Manca P; Sechi LA
Microbiol Spectr; 2022 Aug; 10(4):e0128022. PubMed ID: 35852349
[TBL] [Abstract][Full Text] [Related]
15. Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α.
Mathian A; Breillat P; Dorgham K; Bastard P; Charre C; Lhote R; Quentric P; Moyon Q; Mariaggi AA; Mouries-Martin S; Mellot C; Anna F; Haroche J; Cohen-Aubart F; Sterlin D; Zahr N; Gervais A; Le Voyer T; Bizien L; Amiot Q; Pha M; Hié M; Chasset F; Yssel H; Miyara M; Charneau P; Ghillani-Dalbin P; Casanova JL; Rozenberg F; Amoura Z; Gorochov G
Ann Rheum Dis; 2022 Dec; 81(12):1695-1703. PubMed ID: 35973806
[TBL] [Abstract][Full Text] [Related]
16. Chest Computed Tomography Characteristics of Critically Ill COVID-19 Patients with Auto-antibodies Against Type I Interferons.
Lafont Rapnouil B; Zaarour Y; Arrestier R; Bastard P; Peiffer B; Moncomble E; Parfait M; Bellaïche R; Casanova JL; Mekontso Dessap A; Mule S; de Prost N
J Clin Immunol; 2023 Dec; 44(1):15. PubMed ID: 38129345
[TBL] [Abstract][Full Text] [Related]
17. Type I interferon autoantibodies in hospitalized patients with Middle East respiratory syndrome and association with outcomes and treatment effect of interferon beta-1b in MIRACLE clinical trial.
Alotaibi F; Alharbi NK; Rosen LB; Asiri AY; Assiri AM; Balkhy HH; Al Jeraisy M; Mandourah Y; AlJohani S; Al Harbi S; Jokhdar HAA; Deeb AM; Memish ZA; Jose J; Ghazal S; Al Faraj S; Al Mekhlafi GA; Sherbeeni NM; Elzein FE; AlMutairi BM; Al-Dawood A; Abdullah ML; Barhoumi T; Alenazi MW; Almasood A; Holland SM; Arabi YM;
Influenza Other Respir Viruses; 2023 Mar; 17(3):e13116. PubMed ID: 36960162
[TBL] [Abstract][Full Text] [Related]
18. Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life-Threatening COVID-19 Pneumonia.
Philippot Q; Fekkar A; Gervais A; Le Voyer T; Boers LS; Conil C; Bizien L; de Brabander J; Duitman JW; Romano A; Rosain J; Blaize M; Migaud M; Jeljeli M; Hammadi B; Desmons A; Marchal A; ; ; Mayaux J; Zhang Q; Jouanguy E; Borie R; Crestani B; Luyt CE; Adle-Biassette H; Sene D; Megarbane B; Cobat A; Bastard P; Bos LDJ; Casanova JL; Puel A
J Clin Immunol; 2023 Aug; 43(6):1093-1103. PubMed ID: 37209324
[TBL] [Abstract][Full Text] [Related]
19. Inactive disease in patients with lupus is linked to autoantibodies to type I interferons that normalize blood IFNα and B cell subsets.
Bradford HF; Haljasmägi L; Menon M; McDonnell TCR; Särekannu K; Vanker M; Peterson P; Wincup C; Abida R; Gonzalez RF; Bondet V; Duffy D; Isenberg DA; Kisand K; Mauri C
Cell Rep Med; 2023 Jan; 4(1):100894. PubMed ID: 36652906
[TBL] [Abstract][Full Text] [Related]
20. NFKB2 haploinsufficiency identified via screening for IFN-α2 autoantibodies in children and adolescents hospitalized with SARS-CoV-2-related complications.
Bodansky A; Vazquez SE; Chou J; Novak T; Al-Musa A; Young C; Newhams M; Kucukak S; Zambrano LD; Mitchell A; Wang CY; Moffitt K; Halasa NB; Loftis LL; Schwartz SP; Walker TC; Mack EH; Fitzgerald JC; Gertz SJ; Rowan CM; Irby K; Sanders RC; Kong M; Schuster JE; Staat MA; Zinter MS; Cvijanovich NZ; Tarquinio KM; Coates BM; Flori HR; Dahmer MK; Crandall H; Cullimore ML; Levy ER; Chatani B; Nofziger R; ; Geha RS; DeRisi J; Campbell AP; Anderson M; Randolph AG
J Allergy Clin Immunol; 2023 Apr; 151(4):926-930.e2. PubMed ID: 36509151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
